Thoratec Laboratories
This article was originally published in The Gray Sheet
Executive Summary
Circulatory support and vascular graft device maker plans secondary offering of 4.5 mil. shares of common stock, including 3 mil. shares offered by the company and 1.5 mil. shares sold by an existing shareholder. Lehman Brothers is lead underwriter for the offering, with co-managers Bear Stearns and Adams Harkness & Hill